STAT Plus 6 burning questions about the Senate Finance Committees ambitious new drug pricing plan

STAT Plus: 6 burning questions about the Senate Finance Committee’s ambitious new drug pricing plan

Which drug makers will be hit hardest? Why did pharma’s stocks go up? And other looming questions about the bold Senate drug pricing plan unveiled this week.

More From BioPortfolio on "STAT Plus: 6 burning questions about the Senate Finance Committee’s ambitious new drug pricing plan"